19 completed, 1 terminated. 20 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 19, Terminated 1 |
Follow Comparator: placebo (unspecified): new trials by email Literature Review of Comparator: placebo (unspecified) trials Research Report on Comparator: placebo (unspecified)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041) Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Comparator: placebo (unspecified) - HPV Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 3006 | 2008-12-31 | 2019-02-04 |
| Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy rolofylline, Comparator: Placebo (unspecified) - Heart Failure, Congestive | Phase 3 | Completed | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 480 | 2007-08-01 | 2009-02-20 |
| A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED) ezetimibe (+) simvastatin, Comparator : rosuvastatin calcium, Comparator: Placebo (unspecified) - Hypercholesterolemia | Phase 3 | Completed | Organon and Co | 618 | 2007-02-01 | 2024-05-16 |
| Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED) ezetimibe (+) simvastatin, Comparator: atorvastatin calcium, Comparator: Placebo (unspecified) - Hypercholesterolemia, Metabolic Syndrome | Phase 3 | Completed | Organon and Co | 1143 | 2007-01-01 | 2024-05-16 |
| Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED) montelukast sodium, Comparator: Placebo (unspecified) - Asthma | Phase 3 | Completed | Organon and Co | 1771 | 2006-10-01 | 2024-05-10 |
| PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function rolofylline, Comparator: Placebo (unspecified) - Heart Failure, Congestive | Phase 3 | Completed | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 1102 | 2006-10-01 | 2009-10-09 |
| MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED) sitagliptin phosphate, Comparator: sitagliptin phosphate (MK0431), Comparator: pioglitazone - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 134 | 2006-08-21 | 2017-05-12 |
| PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function rolofylline, Comparator: Placebo (unspecified) - Heart Failure, Congestive | Phase 3 | Completed | NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 932 | 2006-08-01 | 2009-10-09 |
| A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301) montelukast sodium, Comparator: placebo (unspecified) - Asthma | Phase 3 | Completed | Organon and Co | 276 | 2005-07-01 | 2024-05-10 |
| An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED) gaboxadol, Comparator: placebo (unspecified) - Insomnia | Phase 3 | Completed | H. Lundbeck A/S | 900 | 2005-02-01 | 2015-01-14 |
| Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED) gaboxadol, Comparator: placebo (unspecified) - Primary Insomnia | Phase 3 | Completed | H. Lundbeck A/S | 465 | 2004-11-01 | 2015-01-14 |
| An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020) (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, Comparator: placebo (unspecified) - Condylomata Acuminata | Phase 3 | Completed | Merck Sharp & Dohme LLC | 4065 | 2004-09-03 | 2018-08-23 |
| A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED) ezetimibe, Comparator: Placebo (unspecified), simvastatin - Cholesterol | Phase 3 | Completed | Organon and Co | 40 | 2003-07-01 | 2024-08-15 |
| Study MK0767 and Metformin in Type 2 Diabetic Patients (0767-020) MK0767, Comparator: placebo (unspecified), Comparator: metformin - Diabetes Mellitus, Type 2 | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 382 | 2003-05-01 | 2015-06-12 |
| Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201) rofecoxib, Comparator: placebo (unspecified) - Prostate Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 15000 | 2003-01-08 | 2017-05-09 |
| Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED) aprepitant, Comparator: paroxetine HCL, Comparator: Placebo (Unspecified) - Major Depressive Disorder | Phase 3 | Completed | Merck Sharp & Dohme LLC | 600 | 2002-07-30 | 2017-05-05 |
| An Investigational Drug Study in the Treatment of Primary Dysmenorrhea (0663-064) etoricoxib (MK0663), Comparator: placebo (unspecified), Comparator: naproxen sodium - Dysmenorrhea | Phase 3 | Completed | Organon and Co | 129 | 2002-06-07 | 2024-08-15 |
| Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED) aprepitant, Comparator: placebo (unspecified) - Major Depressive Disorder | Phase 3 | Completed | Merck Sharp & Dohme LLC | 800 | 2002-01-03 | 2017-05-05 |
| Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED) aprepitant, Comparator: placebo (unspecified) - Major Depressive Disorder | Phase 3 | Completed | Merck Sharp & Dohme LLC | 540 | 2001-11-21 | 2017-05-05 |
| Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED) aprepitant, Comparator: placebo (unspecified) - Major Depressive Disorder | Phase 3 | Completed | Merck Sharp & Dohme LLC | 450 | 2001-09-01 | 2015-02-09 |
Depressive Disorder, Major (4) · Heart Failure (3) · Renal Insufficiency (3) · Asthma (2) · Diabetes Mellitus, Type 2 (2) · Hypercholesterolemia (2) · Sleep Initiation and Maintenance Disorders (2) · Condylomata Acuminata (1) · Dysmenorrhea (1) · Metabolic Syndrome (1) · Papillomavirus Infections (1) · Prostatic Neoplasms (1)
Merck Sharp & Dohme LLC (9) · Organon and Co (6) · NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (3) · H. Lundbeck A/S (2)
Barry Massie, MD (3) · Christopher O'Connor, MD (3) · Marco Metra, MD (2)
PMID 18926433, PMID 20925544, PMID 21545947, PMID 21900185, PMID 22339573, PMID 24281134, PMID 24281137, PMID 27448534, PMID 27658757, PMID 29748350, PMID 19380898, PMID 20191935, PMID 20306820, PMID 21050476, PMID 21288094, PMID 21624752, PMID 21859750, PMID 22029979, PMID 22108151, PMID 23831322, PMID 26336957, PMID 27266853, PMID 27507112, PMID 28069685, PMID 28624483, PMID 30638797, PMID 31926466, PMID 32184277, PMID 34265048, PMID 34780705, PMID 38012959, PMID 41162330, PMID 41276263, PMID 41400842
2004 (1)